» Articles » PMID: 39195022

Biohybrids for Combined Therapies of Skin Wounds: Agglomerates of Mesenchymal Stem Cells with Gelatin Hydrogel Beads Delivering Phages and Basic Fibroblast Growth Factor

Overview
Journal Gels
Date 2024 Aug 28
PMID 39195022
Authors
Affiliations
Soon will be listed here.
Abstract

There is great interest in developing effective therapies for the treatment of skin wounds accompanied by deep tissue losses and severe infections. We have attempted to prepare biohybrids formed of agglomerates of mesenchymal stem cells (MSCs) with gelatin hydrogel beads (GEL beads) delivering bacteriophages (phages) as antibacterial agents and/or basic fibroblast growth factor (bFGF) for faster and better healing, providing combined therapies for these types of skin wounds. The gelatin beads were produced through a two-step process using basic and/or acidic gelatins with different isoelectric points. () and its specific T4 phages were propagated. Phages and/or bFGF were loaded within the GELs and their release rates and modes were obtained. The phage release from the basic GEL beads was quite fast; in contrast, the bFGF release from the acidic GEL beads was sustained, as anticipated. MSCs were isolated from mouse adipose tissues and 2D-cultured. Agglomerates of these MSCs with GEL beads were formed and maturated in 3D cultures, and their time-dependent changes were followed. In these 3D culture experiments, it was observed that the agglomerates with GEL beads were very healthy and the MSCs formed tissue-like structures in 7 days, while the MSC agglomerates were not healthy and shrunk considerably as a result of cell death.

References
1.
Royer S, Morais A, Batistao D . Phage therapy as strategy to face post-antibiotic era: a guide to beginners and experts. Arch Microbiol. 2021; 203(4):1271-1279. DOI: 10.1007/s00203-020-02167-5. View

2.
Dhingra S, Rahman N, Peile E, Rahman M, Sartelli M, Hassali M . Microbial Resistance Movements: An Overview of Global Public Health Threats Posed by Antimicrobial Resistance, and How Best to Counter. Front Public Health. 2020; 8:535668. PMC: 7672122. DOI: 10.3389/fpubh.2020.535668. View

3.
Anyaegbunam N, Anekpo C, Anyaegbunam Z, Doowuese Y, Chinaka C, Odo O . The resurgence of phage-based therapy in the era of increasing antibiotic resistance: From research progress to challenges and prospects. Microbiol Res. 2022; 264:127155. DOI: 10.1016/j.micres.2022.127155. View

4.
Pirnay J . Phage Therapy in the Year 2035. Front Microbiol. 2020; 11:1171. PMC: 7284012. DOI: 10.3389/fmicb.2020.01171. View

5.
Lukin I, Erezuma I, Maeso L, Zarate J, Federico Desimone M, Al-Tel T . Progress in Gelatin as Biomaterial for Tissue Engineering. Pharmaceutics. 2022; 14(6). PMC: 9229474. DOI: 10.3390/pharmaceutics14061177. View